Adaptive Biotechnologies (ADPT) Gains from Sales and Divestitures (2019 - 2026)

Adaptive Biotechnologies (ADPT) has 8 years of Gains from Sales and Divestitures data on file, last reported at $1.4 million in Q1 2026.

• Quarterly Gains from Sales and Divestitures fell 52.93% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 52.93% YoY) and the FY2025 annual result came in at $247117.0, down 90.45% from the prior year.
• Gains from Sales and Divestitures rose to $1.4 million in Q1 2026 per ADPT's latest filing, from $247117.0 in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $3.0 million in Q1 2025, with the low at $141185.0 in Q1 2022.
• Average Gains from Sales and Divestitures over 5 years is $1.2 million, with a median of $1.2 million recorded in 2023.
• Year-over-year, Gains from Sales and Divestitures soared 1524.73% in 2022 and slumped 90.45% in 2025.
• Adaptive Biotechnologies' Gains from Sales and Divestitures stood at $304637.0 in 2022, then soared by 394.64% to $1.5 million in 2023, then jumped by 71.73% to $2.6 million in 2024, then tumbled by 90.45% to $247117.0 in 2025, then jumped by 474.0% to $1.4 million in 2026.
• Business Quant data shows ADPT's Gains from Sales and Divestitures at $1.4 million in Q1 2026, $247117.0 in Q4 2025, and $247117.0 in Q3 2025.